Risultati per: Scoperto nuovo biomarker per il cancro al colon-retto

Studio italiano, la chiave è in una particolare trasformazione delle cellule

Colonoscopy, a crucial procedure for detecting and removing colorectal polyps, has seen transformative advancements through the integration of Artificial Intelligence (AI), specifically in Computer-Aided Detection (CADe) and Diagnosis (CADx). These tools enhance real-time detection and characterization of lesions, potentially reducing human error, and standardizing the quality of colonoscopy across endoscopists. CADe has proven effective in increasing adenoma detection rate, potentially reducing long-term colorectal cancer incidence.

Iniziativa all’Università Politecnica delle Marche

This narrative review explores the potential of biomarker-directed personalized radiotherapy approaches.

This cross-sectional study identifies variables in cardiac biomarker testing and their association with acute coronary syndrome incidence among adults visiting the emergency department.

This cohort study examines if the approval of precision oncology therapies has benefited patients with cancer from various ancestral backgrounds equally over time.

Ai primi test porta sviluppo di cellule immunitarie anti-tumore

This clinical trial assessed whether treatment protocols for monitoring C-reactive protein or procalcitonin safely reduced the amount of time critically ill adults with suspected sepsis received antibiotics while maintaining treatment safety measured by 28-day all-cause mortality.

Si rafforza collaborazione tra Istituti, verso progetti comuni

Introduction
All grade 2/3 gliomas are incurable and at the time of inevitable relapse, patients have significant unmet needs with few effective treatments. This study aims to improve outcomes by molecular profiling of patients at relapse, then matching them with the best available drug based on their molecular profile, maximising the chances of patient benefit while simultaneously testing multiple novel drugs.

Methods and analysis
Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2) will be an international, phase 2, multicentre, open-label, biomarker-directed, umbrella clinical trial for recurrent isocitrate dehydrogenase mutant, histologically grade 2/3 gliomas. Investigational treatment will be assigned based on molecular profiling of contemporaneous tissue obtained at disease relapse using next-generation sequencing. LUMOS-2 will begin with three therapeutic treatment arms: paxalisib, cadonilimab and selinexor. Patient molecular profiles will be assessed by an expert, multidisciplinary Molecular Tumour Advisory Panel. Patients whose molecular profile is considered suitable for a targeted agent like paxalisib will be allocated to that arm, others will be randomised to the available arms of the trial. The primary endpoint is progression-free survival at 6 months. Secondary objectives include assessment of overall survival, response rate, safety and quality of life measures. Two additional therapeutic arms are currently in development.

Ethics and dissemination
Central ethics approval was obtained from the Sydney Local Health District Ethics Review Committee, Royal Prince Alfred Hospital Zone, Sydney, Australia (Approval: 2022/ETH02230). Other clinical sites will provide oversight through local governance processes, including obtaining informed consent from suitable participants. A report describing the results of the study will be submitted to international meetings and peer-reviewed journals.

Trial registration number
ACTRN12623000096651.

L’organizzazione accoglie a Roma chi viene da fuori per le cure